Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade

Description of Omburtamab Biosimilar - Anti-CD276, B7-H3, B7RP-2 mAb - Research Grade

Introduction to Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb

Omburtamab Biosimilar, also known as Anti-CD276, B7-H3, B7RP-2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancer. This biosimilar is designed to target the CD276 protein, also known as B7-H3 or B7RP-2, which is overexpressed in many types of cancer cells. In this article, we will explore the structure, activity, and potential applications of Omburtamab Biosimilar.

Structure of Omburtamab Biosimilar

Omburtamab Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to specifically target the CD276 protein. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of about 21 days.

The binding site of Omburtamab Biosimilar is located on the Fc region of the antibody, which allows for interaction with immune cells and activation of immune responses. The variable regions of the antibody, also known as the antigen-binding sites, are responsible for binding to the CD276 protein on the surface of cancer cells.

Activity of Omburtamab Biosimilar

The main activity of Omburtamab Biosimilar is its ability to bind to the CD276 protein on the surface of cancer cells. This binding triggers a series of immune responses, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These responses result in the destruction of cancer cells and inhibition of tumor growth.

In addition, Omburtamab Biosimilar has been shown to have a direct anti-tumor effect by inducing apoptosis, or programmed cell death, in cancer cells. This is achieved by blocking the signaling pathways involved in cancer cell survival and proliferation.

Applications of Omburtamab Biosimilar

Omburtamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including neuroblastoma, melanoma, and lung cancer. It has also been investigated for its potential to treat other diseases, such as autoimmune disorders and infectious diseases.

In neuroblastoma, Omburtamab Biosimilar has shown to be effective in targeting and killing cancer cells, while sparing healthy cells. This makes it a potential treatment option for this aggressive form of childhood cancer.

In melanoma, Omburtamab Biosimilar has been shown to enhance the anti-tumor effects of other therapies, such as chemotherapy and immune checkpoint inhibitors. This makes it a promising candidate for combination therapy in the treatment of this deadly form of skin cancer.

In lung

cancer, Omburtamab Biosimilar has shown to be effective in targeting cancer cells that have become resistant to chemotherapy. It has also been shown to enhance the activity of other targeted therapies, such as EGFR inhibitors.

Conclusion

In summary, Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade is a promising monoclonal antibody that has been designed to target the CD276 protein, which is overexpressed in many types of cancer cells. Its unique structure and activity make it a potential treatment option for various types of cancer, including neuroblastoma, melanoma, and lung cancer. Omburtamab Biosimilar is currently being evaluated in clinical trials and has the potential to improve the outcomes of cancer patients.

Omburtamab Biosimilar - Anti-CD276, B7-H3, B7RP-2 mAb binds to CD276 Recombinant Protein in indirect ELISA Assay

Immobilized CD276 Recombinant Protein (cat. No.PX-P4125) at 0.5µg/mL (100µL/well) can bind to Omburtamab Biosimilar - Anti-CD276, B7-H3, B7RP-2 mAb (cat. No.PX-TA1532) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450